États-Unis · Plateformes & données · Finviz

Seres Therapeutics Announces Publication of SER-155 Phase 1b Results in Nature Medicine Showing Reduced Bloodstream Infections in Allogeneic Hematopoietic Cell Transplantation ...

Publié par Finviz · États-Unis il y a 14 h

CAMBRIDGE, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE)-- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that results from its Phase 1b…

Lire l'article complet sur Finviz Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (finviz.com)

Seres Therapeutics Announces Publication of SER-155 Phase 1b Results in Nature Medicine Showing Reduced Bloodstream Infections in Allogeneic Hematopoietic Cell Transplantation ...

À lire aussi

Offerpad (OPAD) Q3 2026 Earnings Call Transcript

Delta blasts a Heathrow Airport operational decision

Axa Sa (OTCMKTS:AXAHY) Stock Now Rated "Moderate Buy" by Wall Street Brokerages

3 signs cash-strapped consumers are nearing a ‘spend-pocalypse’ that would hurt the economy

Taco Bell sales fall more than expected on cyclosporiasis outbreak hit

Best Biotech Stocks Right Now

Seres Therapeutics Announces Publication of SER-155 Phase 1b Results in Nature Medicine Showing Reduced Bloodstream Infections in Allogeneic Hematopoietic Cell Transplantation ...

Partager

À lire aussi

Offerpad (OPAD) Q3 2026 Earnings Call Transcript

Delta blasts a Heathrow Airport operational decision

Axa Sa (OTCMKTS:AXAHY) Stock Now Rated "Moderate Buy" by Wall Street Brokerages

3 signs cash-strapped consumers are nearing a ‘spend-pocalypse’ that would hurt the economy

Taco Bell sales fall more than expected on cyclosporiasis outbreak hit

Best Biotech Stocks Right Now